Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the best strong buy stocks to invest in according to Wall Street. On September 24, Wells Fargo analyst Derek Archila reiterated a Buy rating on Soleno Therapeutics, Inc. (NASDAQ:SLNO) and set a price target of $123.00. Why Soleno Therapeutics Inc. (SLNO) Went Up Last Week? Soleno Therapeutics, Inc. (NASDAQ:SLNO) reported that it used $12.6 million of cash in its operating activities during the three months ended June 30, 2025. Management reported that the ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Soleno (SLNO) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Soleno and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a nationally recognize ...

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Soleno and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On Augu ...

BREAKING: Futures Edge Up, Alibaba Leads China Stocks Higher Shares of Acadia Pharmaceuticals (ACAD) toppled Wednesday after the biotech company's experimental treatment for a rare, genetic disorder failed in Phase 3 testing. Analysts largely expected the drug, dubbed carbetocin, to miss its mark in patients with Prader-Willi syndrome. In this condition, a deletion or mutation of a specific gene causes physical, intellectual, developmental and behavioral symptoms. Acadia intended for its drug to treat exces ...

In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Soleno Therapeutics, Inc. is one of them. Soleno Therapeutics, Inc. (NASDAQ:SLNO) tops our list for being one of the most oversold stocks. It is a clinical-stage biotech focused on rare diseases and has seen significant stock volatility in 2025 following the commercial launch of its lead product, VYKAT XR, the first FDA-approved treatment for hyperphagia in Prader-Willi Syndrome (PWS). The therapy addresses ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?When I last covered Soleno Therapeutics (NASDAQ: SLNO ), it was late March, and the Redwood City, California-based biotech had just announced the approval of its drug Vykat (diazoxide choline) to treat patients aged ...

公司调查事件 - 律师事务所Pomerantz LLP正在调查Soleno Therapeutics公司及其部分高管是否涉及证券欺诈或其他非法商业行为 [1] - 调查涉及投资者可能因公司不当行为遭受损失的情况 [1] 股价波动 - Scorpion Capital于2025年8月15日发布报告称Soleno唯一产品Vykat XR定价过高且对儿童可能存在安全隐患 [2] - 报告发布当日公司股价下跌5.73美元/股，跌幅达7.41%，收盘报71.63美元/股 [2] 相关业务背景 - Pomerantz LLP在纽约、芝加哥、洛杉矶、伦敦、巴黎和特拉维夫设有办公室，专长于公司证券和反垄断集体诉讼领域 [3] - 该律所历史上曾为集体诉讼成员追回多个数百万美元的损害赔偿 [3]

股价表现与市场情绪 - 过去四周股价下跌26% 主要受抛售压力影响 [1] - 当前进入超卖区域 RSI指标为28.11 低于30的超卖临界值 [2][5] - 技术指标显示抛售压力可能耗尽 股价存在反弹需求 [3][5] 基本面支撑因素 - 华尔街分析师普遍上调盈利预期 共识EPS预估在过去30天内上调26.1% [7] - 卖方分析师对当前年度盈利预估形成强烈共识 [7] - 盈利预估上调趋势通常推动短期价格上涨 [7] 专业机构评级 - 当前获得Zacks排名第2级（买入） 位列其覆盖的4000多只股票中前20% [8] - 排名基于盈利预估修正趋势和EPS超预期表现 [8] - 该排名被视为近期潜在反弹的更明确指标 [8] 技术指标分析 - RSI作为动量振荡指标 用于衡量价格变动速度和变化 [2] - 指标在0-100间震荡 低于30视为超卖 [2] - 所有股票都在超买和超卖间震荡 与基本面质量无关 [3]

OAKLAND, Calif.--(BUSINESS WIRE)---- $SLNO #SLNO--Gibbs Mura is investigating legal claims on behalf of investors of Soleno Therapeutics, Inc. (NASDAQ: SLNO). ...

LOS ANGELES--(BUSINESS WIRE)---- $SLNO--SLNO Investors Have Opportunity to Join Soleno Therapeutics, Inc. Fraud Investigation with the Schall Law Firm. ...